Biotech & Pharma

BreezeBio banks $60M to make more precise genetic medicines

26 sec read12 views0 listens

BreezeBio, formerly known as GenEdit, secured $60M funding to pivot towards developing its own genetic medicines, initially targeting a therapy to induce tolerance in Type 1 diabetes patients. This shift underscores the company's ambition to create more precise treatments, potentially offering new hope for genetic disease management and setting a precedent for other biotech firms to innovate directly within their therapeutic pipelines.

Read the full article at BioPharma Dive

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Legal & Policy8 hours ago25 sec read

What A Torn Rotator Cuff Can Teach Us About Legal Business Development

A business development coach shares lessons from his recovery from a torn rotator cuff, drawing parallels between physical rehabilitation and building a successful law practice. He emphasizes that achieving goals requires sacrifice, following a struc...

Ali Nemati

Biotech & Pharma11 hours ago23 sec read

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Aprea Therapeutics is accelerating enrollment in its Phase I trial of APR-1051, a WEE1 kinase inhibitor, after observing early signs of clinical activity. This expansion aims to gather more data on the drug's efficacy and safety, particularly for pat...

Ali Nemati

Biotech & Pharma11 hours ago29 sec read

The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates

Cindy Cheng, PhD, will discuss the development of dual-payload antibody-drug conjugates (dp-ADCs) to enhance efficacy and overcome drug resistance in cancer treatments. This innovation is crucial for biotech and pharma developers aiming to improve th...

Ali Nemati